OTCMKTS:POLXF - Polydex Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.14 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.14
Today's Range$1.14 - $1.14
52-Week Range$0.87 - $1.50
VolumeN/A
Average Volume9,939 shs
Market Capitalization$3.85 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.38

About Polydex Pharmaceuticals (OTCMKTS:POLXF)

Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

Receive POLXF News and Ratings via Email

Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:POLXF
CUSIPN/A
Phone416-755-2231

Debt

Debt-to-Equity Ratio0.05
Current Ratio4.27
Quick Ratio3.15

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.28 million
Price / Sales0.73
Cash Flow$0.2065 per share
Price / Cash5.52
Book Value$1.70 per share
Price / Book0.67

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$440,000.00
Net Margins8.32%
Return on Equity8.19%
Return on Assets6.36%

Miscellaneous

EmployeesN/A
Outstanding Shares3,380,000

Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions

What is Polydex Pharmaceuticals' stock symbol?

Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."

How were Polydex Pharmaceuticals' earnings last quarter?

Polydex Pharmaceuticals Limited (OTCMKTS:POLXF) announced its quarterly earnings results on Tuesday, May, 1st. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $1.31 million for the quarter. Polydex Pharmaceuticals had a return on equity of 8.19% and a net margin of 8.32%. View Polydex Pharmaceuticals' Earnings History.

When is Polydex Pharmaceuticals' next earnings date?

Polydex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Polydex Pharmaceuticals.

Who are some of Polydex Pharmaceuticals' key competitors?

Who are Polydex Pharmaceuticals' key executives?

Polydex Pharmaceuticals' management team includes the folowing people:
  • Mr. George G. Usher, Chairman, CEO, Pres, Pres of Chemdex Inc and VP of Dextran Products Ltd (Age 59)
  • Mr. John Alfred Luce C.A., Chief Financial Officer and Principal Accounting Officer (Age 71)
  • Ms. Sharon L. Wardlaw, Chief Operating Officer, Treasurer, Sec. and Pres of Dextran Products Limited (Age 65)

Has Polydex Pharmaceuticals been receiving favorable news coverage?

News articles about POLXF stock have been trending somewhat positive on Friday, Accern reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Polydex Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Polydex Pharmaceuticals' stock price today?

One share of POLXF stock can currently be purchased for approximately $1.14.

How big of a company is Polydex Pharmaceuticals?

Polydex Pharmaceuticals has a market capitalization of $3.85 million and generates $5.28 million in revenue each year.

How can I contact Polydex Pharmaceuticals?

Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231.


MarketBeat Community Rating for Polydex Pharmaceuticals (POLXF)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Polydex Pharmaceuticals (OTCMKTS:POLXF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/25/2016 forward)

Earnings

Polydex Pharmaceuticals (OTCMKTS:POLXF) Earnings History and Estimates Chart

Earnings by Quarter for Polydex Pharmaceuticals (OTCMKTS:POLXF)

Polydex Pharmaceuticals (OTCMKTS POLXF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018        
5/1/2018Q4 2018$0.03$1.31 millionViewN/AView Earnings Details
12/15/2017Q3 2018$0.07$1.44 millionViewN/AView Earnings Details
5/1/2017Q4 2017$0.02$1.98 millionViewN/AView Earnings Details
12/15/2016Q3 2017$0.07$1.45 millionViewN/AView Earnings Details
9/15/2016Q2 2017$0.08$1.74 millionViewN/AView Earnings Details
6/14/2016Q1 2017$0.02$1.46 millionViewN/AView Earnings Details
5/2/2016Q4 2016$0.04$1.38 millionViewN/AView Earnings Details
12/15/2015Q3 2016$0.12$1.42 millionViewN/AView Earnings Details
9/15/2015Q2 2016$0.12$1.68 millionViewN/AView Earnings Details
6/10/2015Q1 2016$0.09$1.56 millionViewN/AView Earnings Details
4/30/2015Q4 2015$0.09$1.39 millionViewN/AView Earnings Details
12/15/2014Q3 2015$0.03$1.30 millionViewN/AView Earnings Details
9/9/2014Q2 2015$0.02$1.27 millionViewN/AView Earnings Details
6/10/2014Q1 2015$0.02$1.41 millionViewN/AView Earnings Details
5/1/2014Q4 2014$0.04$1.34 millionViewN/AView Earnings Details
12/11/2013Q3$0.01$1.32 millionViewN/AView Earnings Details
9/16/2013Q2 2014$0.06$1.87 millionViewN/AView Earnings Details
6/10/2013Q1 2014$0.08$1.44 millionViewN/AView Earnings Details
4/30/2013Q4 2013($0.02)$1.50 millionViewN/AView Earnings Details
12/14/2012Q3 2013($0.04)ViewN/AView Earnings Details
9/17/2012Q2 2013($0.03)ViewN/AView Earnings Details
6/15/2012Q1 2013($0.04)ViewN/AView Earnings Details
4/30/2012Q4 2012($0.02)ViewN/AView Earnings Details
12/15/2011Q3 2012$0.03ViewN/AView Earnings Details
6/13/2011Q1 2012$0.05ViewN/AView Earnings Details
5/4/2011Q4 2011($0.08)ViewN/AView Earnings Details
12/15/2010Q3 2011($0.01)ViewN/AView Earnings Details
9/15/2010Q2 2011($0.11)ViewN/AView Earnings Details
6/15/2010Q1 2011($0.03)ViewN/AView Earnings Details
5/3/2010Q4 2010($0.45)ViewN/AView Earnings Details
12/15/2009Q3 2010($0.07)ViewN/AView Earnings Details
9/14/2009Q2 2010($0.16)ViewN/AView Earnings Details
6/15/2009Q1 2010($0.02)ViewN/AView Earnings Details
12/12/2008Q3 2009($0.14)ViewN/AView Earnings Details
9/12/2008Q2 2009($0.04)ViewN/AView Earnings Details
6/13/2008Q1 2009($0.01)ViewN/AView Earnings Details
4/30/2008Q4 2008($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Polydex Pharmaceuticals (OTCMKTS:POLXF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Polydex Pharmaceuticals (OTCMKTS POLXF) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.90%
Insider Trading History for Polydex Pharmaceuticals (OTCMKTS:POLXF)

Polydex Pharmaceuticals (OTCMKTS POLXF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Polydex Pharmaceuticals (OTCMKTS POLXF) News Headlines

Source:

SEC Filings

Polydex Pharmaceuticals (OTCMKTS:POLXF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Polydex Pharmaceuticals (OTCMKTS:POLXF) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Polydex Pharmaceuticals (OTCMKTS POLXF) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.